Equity · Healthcare
EHC
NYSEEncompass Health (EHC)
The line runs $123.13 on 17 September through $126 on 22 October, on a scale from $115 to $130. Days the market did not trade hold the previous close, flat.
- Market cap
- $12.4B
- P/E (TTM)
- 20.5
- 52-week range
- $94 – $127.85
- Avg volume
- 101.5K
as of Oct 22, 2026
Have Encompass Health (EHC) insiders bought or sold shares recently?
In the 90 days to 28 Oct 2026, Encompass Health insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 15 Oct 2025, show no open-market purchase.
Form 4, 90 days to 28 Oct 2026, newest reported trade 31 Aug 2026
Buys 0Sells 5Net sold $26.43MOther filings 12
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 31 Aug 2026 | Darby John PatrickEVP, Gen Counsel & Secretary | Sell | 4,858 | $588K |
| 31 Aug 2026 | Price Andrew LChief Accounting Officer | Sell | 5,211 | $630K |
| 10 Aug 2026 | COLTHARP DOUGLAS EEVP & Chief Financial Officer | Sell | 18,869 | $2.37M |
| 10 Aug 2026 | Darby John PatrickEVP, Gen Counsel & Secretary | Sell | 8,906 | $1.12M |
| 10 Aug 2026 | Tarr Mark JPresident & CEO | Sell | 173,148 | $21.72M |
| Sold | 5 open-market sales | 210,992 | $26.43M |
12 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 19 Oct 2026 | Christie Edward M IIIDirector | Award | 221 | $28K |
| 19 Oct 2026 | Reidy Christopher RDirector | Award | 284 | $36K |
| 15 Oct 2026 | CARMICHAEL GREG DDirector | Award | 28 | |
| 15 Oct 2026 | Christie Edward M IIIDirector | Award | 11 | |
| 15 Oct 2026 | KATZ LESLYE GDirector | Award | 81 | |
| 15 Oct 2026 | O'Connor Kevin J.Director | Award | 18 | |
| 15 Oct 2026 | Hayes Cain ADirector | Award | 4 | |
| 15 Oct 2026 | Reidy Christopher RDirector | Award | 20 | |
| 15 Oct 2026 | HERMAN JOAN EDirector | Award | 81 | |
| 15 Oct 2026 | SCHLICHTING NANCY MDirector | Award | 38 | |
| 15 Oct 2026 | Williams TerranceDirector | Award | 28 | |
| 31 Aug 2026 | Darby John PatrickEVP, Gen Counsel & Secretary | Option exercise | 4,858 | $170K |
Which funds hold Encompass Health (EHC)?
11 of the 45 institutional funds we track reported a Encompass Health position for the quarter ended 30 Jun 2026 — a combined $720.2M; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Citadel Advisors | Added | 2,563,104 | $259.1M | +400.7% |
| Two Sigma Investments | Held (±25%) | 2,267,668 | $229.2M | +2.1% |
| Millennium Management | Added | 805,717 | $81.4M | +68.6% |
| AQR Capital Management | Held (±25%) | 561,888 | $56.6M | +12.2% |
| D. E. Shaw & Co. | Trimmed | 384,595 | $38.9M | −32.0% |
| Balyasny Asset Management | Added | 296,939 | $30.0M | +451.3% |
| Renaissance Technologies | Trimmed | 174,500 | $17.6M | −34.2% |
| Bridgewater Associates | Held (±25%) | 41,016 | $4.1M | −11.6% |
| Man Group | Trimmed | 24,486 | $2.5M | −85.1% |
| GAMCO Investors | Held (±25%) | 5,507 | $557K | +14.4% |
Showing the 10 largest of 11 reported positions. The figures above count all of them.
Have members of Congress traded Encompass Health (EHC)?
The most recent congressional trade disclosed in Encompass Health is a sale by Lisa C. McClain (house, MI), dated 31 Oct 2025.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 31 Oct 2025 | Lisa C. McClainhouse · Republican–MI | Sale | $1K–$15K | 21 days |
| 30 Oct 2025 | Lisa C. McClainhouse · Republican–MI | Purchase | $1K–$15K | 22 days |
| 30 Oct 2025 | Lisa C. McClainhouse · Republican–MI | Sale | $1K–$15K | 22 days |
| 22 Jul 2025 | Lisa C. McClainhouse · Republican–MI | Purchase | $1K–$15K | 22 days |
| 27 Aug 2020 | Susie Leehouse · Democrat–NV | Sale | $1K–$15K | 41 days |
| 19 May 2020 | Susie Leehouse · Democrat–NV | Purchase | $1K–$15K | 27 days |
| 31 Jul 2019 | Susie Leehouse · Democrat–NV | Sale | $1K–$15K | 29 days |
| 15 Mar 2019 | Susie Leehouse · Democrat–NV | Purchase | $1K–$15K | 24 days |
What has been filed or recorded for Encompass Health (EHC)?
The filings we hold for Encompass Health, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 2 shares | $247 notional · <0.001% of shares out |
| 15 Sep 2026 | Fails to deliver | Shares failed to deliver | 191 shares | $23K notional · <0.001% of shares out |
| 14 Sep 2026 | Fails to deliver | Shares failed to deliver | 8 shares | $974 notional · <0.001% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS $1.54 | |
| 30 Jun 2026 | Financials | Total assets | $7.5B | at period end |
| 30 Jun 2026 | Financials | Total equity | $2.6B | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS $1.93 | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS $5.54 | |
| 31 Dec 2025 | Financials | Revenue | $5.9B | fiscal year |
| 31 Dec 2025 | Financials | Net income | $566.2M | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | $5.54 | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS $1.24 | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS $1.39 | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS $1.48 | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS $4.46 | |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS $1.06 |
Encompass Health (EHC): frequently asked questions
What did Encompass Health shares close at?
Encompass Health closed at $126.00 on 22 Oct 2026, up 4.13% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Encompass Health’s market cap?
Encompass Health is worth $12.4B by market value as of 22 Oct 2026, which is the share price times the shares on issue from its SEC filings.
What is Encompass Health’s P/E ratio?
Encompass Health has a price-to-earnings ratio of 20.5, as of 22 Oct 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Encompass Health’s revenue?
Encompass Health reported revenue of $5.9B for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Encompass Health insiders bought or sold shares recently?
In the 90 days to 28 Oct 2026, Encompass Health insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 15 Oct 2025, show no open-market purchase. A further 12 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Encompass Health?
11 of the 45 funds we track reported a Encompass Health position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Two Sigma Investments and Millennium Management. See Funds
Have members of Congress traded Encompass Health?
Yes. 8 trades in Encompass Health appear in the congressional disclosures we hold; the latest is a sale by Lisa C. McClain (House, MI) dated 31 Oct 2025, filed 21 Nov 2025. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Encompass Health last report earnings?
Encompass Health last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $1.54; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings